TerminatedPhase 1NCT04327011
A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
Studying Anaplastic astrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tocagen Inc.
- Principal Investigator
- Asha Das, MDTocagen Inc.
- Intervention
- Toca 511 vector(biological)
- Enrollment
- 65 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2011 – 2019
Study locations (11)
- University of California, Los Angeles, Los Angeles, California, United States
- UCSD, San Diego, California, United States
- UCSF, San Francisco, California, United States
- Henry Ford Health System, Detroit, Michigan, United States
- JFK Medical Center Neuroscience Institute, Edison, New Jersey, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- John Theurer Cancer Center at Hackensack University, Hackensack, New Jersey, United States
- Cleveland Clinic Foundation, Cleveland, Ohio, United States
- Ohio State University, Columbus, Ohio, United States
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
- Swedish Neuroscience Institute, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04327011 on ClinicalTrials.govOther trials for Anaplastic astrocytoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07448480Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant GliomasBlokhin's Russian Cancer Research Center
- RECRUITINGEARLY PHASE1NCT06333899Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK FusionNationwide Children's Hospital
- RECRUITINGPHASE1, PHASE2NCT05956821Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of AgeUniversity of Miami
- ACTIVE NOT RECRUITINGPHASE1NCT06614855A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant GliomaJames Markert, MD
- RECRUITINGPHASE2NCT06161974Study of Olutasidenib and Temozolomide in HGGRigel Pharmaceuticals
- RECRUITINGPHASE2NCT05843253Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantNationwide Children's Hospital
- RECRUITINGNCT05839379Targeted Pediatric High-Grade Glioma TherapyNationwide Children's Hospital
- RECRUITINGPHASE2NCT06264388DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic AstrocytomaAshish Shah